Solventum Seen Positioned for Meaningful Re-Rating Over Next 12 to 18 Months, Wedbush Says

MT Newswires Live05-15

Solventum (SOLV) shows a convergence of catalysts that should drive a meaningful valuation re-rating over the next 12 to 18 months, Wedbush Securities said in a Friday research note.

The brokerage said its investment thesis on Solventum centers on the divestiture or spin-off of its non-core Dental Solutions and Health Info Systems segments, adding that these businesses are "strategically misaligned" with the core Medical Surgical segment.

With activist investor Trian escalating its campaign for portfolio simplification, the company's "Transform for the Future" program targets EBIT margins between 23% and 25% by fiscal 2028 and includes the $4 billion Purification & Filtration divestiture. Wedbush said Solventum is seeing a convergence of catalysts that could unlock shareholder value.

The investment firm added that Solventum's stock offers an attractive entry point at current levels for investors seeking exposure to a differentiated medical technology portfolio with identifiable near-term catalysts, activist accountability, and a clear path to pure-play re-rating.

Wedbush initiated coverage with an outperform rating and a $94 price target.

Price: 75.43, Change: +1.01, Percent Change: +1.36

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2635228033?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-15 22:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2635228033","market":"sh","top_or_hot":-1,"title":"Solventum Seen Positioned for Meaningful Re-Rating Over Next 12 to 18 Months, Wedbush Says","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/SOLV\">Solventum</a> (SOLV) shows a convergence of catalysts that should drive a meaningful valuation re-rating over the next 12 to 18 months, Wedbush Securities said in a Friday research note.</p><p>The brokerage said its investment thesis on Solventum centers on the divestiture or spin-off of its non-core Dental Solutions and Health Info Systems segments, adding that these businesses are \"strategically misaligned\" with the core Medical Surgical segment.</p><p>With activist investor Trian escalating its campaign for portfolio simplification, the company's \"Transform for the Future\" program targets EBIT margins between 23% and 25% by fiscal 2028 and includes the $4 billion Purification &amp; Filtration divestiture. Wedbush said Solventum is seeing a convergence of catalysts that could unlock shareholder value.</p><p>The investment firm added that Solventum's stock offers an attractive entry point at current levels for investors seeking exposure to a differentiated medical technology portfolio with identifiable near-term catalysts, activist accountability, and a clear path to pure-play re-rating.</p><p>Wedbush initiated coverage with an outperform rating and a $94 price target.</p><p>Price: 75.43, Change: +1.01, Percent Change: +1.36</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Solventum Seen Positioned for Meaningful Re-Rating Over Next 12 to 18 Months, Wedbush Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSolventum Seen Positioned for Meaningful Re-Rating Over Next 12 to 18 Months, Wedbush Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-05-15 22:45</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/SOLV\">Solventum</a> (SOLV) shows a convergence of catalysts that should drive a meaningful valuation re-rating over the next 12 to 18 months, Wedbush Securities said in a Friday research note.</p><p>The brokerage said its investment thesis on Solventum centers on the divestiture or spin-off of its non-core Dental Solutions and Health Info Systems segments, adding that these businesses are \"strategically misaligned\" with the core Medical Surgical segment.</p><p>With activist investor Trian escalating its campaign for portfolio simplification, the company's \"Transform for the Future\" program targets EBIT margins between 23% and 25% by fiscal 2028 and includes the $4 billion Purification &amp; Filtration divestiture. Wedbush said Solventum is seeing a convergence of catalysts that could unlock shareholder value.</p><p>The investment firm added that Solventum's stock offers an attractive entry point at current levels for investors seeking exposure to a differentiated medical technology portfolio with identifiable near-term catalysts, activist accountability, and a clear path to pure-play re-rating.</p><p>Wedbush initiated coverage with an outperform rating and a $94 price target.</p><p>Price: 75.43, Change: +1.01, Percent Change: +1.36</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SOLV","symbol_name":"Solventum","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2635228033","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2635228033","pubTimestamp":1778856349,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Solventum  shows a convergence of catalysts that should drive a meaningful valuation re-rating over the next 12 to 18 months, Wedbush Securities said in a Friday research note.The brokerage said its investment thesis on Solventum centers on the divestiture or spin-off of its non-core Dental Solutions and Health Info Systems segments, adding that these businesses are \"strategically misaligned\" with the core Medical Surgical segment.With activist investor Trian escalating its campaign for portfolio simplification, the company's \"Transform for the Future\" program targets EBIT margins between 23% and 25% by fiscal 2028 and includes the $4 billion Purification & Filtration divestiture. Wedbush said Solventum is seeing a convergence of catalysts that could unlock shareholder value.The investment firm added that Solventum's stock offers an attractive entry point at current levels for investors seeking exposure to a differentiated medical technology portfolio with identifiable near-term cataly","collect":0,"end_time":0,"defaultTopTitle":"","property":["rate"],"viewcount":null,"language":"en","relate_stocks":{"SOLV":"Solventum"},"translate_title":"Wedbush表示，Solventum有望在未来12至18个月内进行有意义的重新评级","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SOLV":1.5},"content_text":"Solventum (SOLV) shows a convergence of catalysts that should drive a meaningful valuation re-rating over the next 12 to 18 months, Wedbush Securities said in a Friday research note.The brokerage said its investment thesis on Solventum centers on the divestiture or spin-off of its non-core Dental Solutions and Health Info Systems segments, adding that these businesses are \"strategically misaligned\" with the core Medical Surgical segment.With activist investor Trian escalating its campaign for portfolio simplification, the company's \"Transform for the Future\" program targets EBIT margins between 23% and 25% by fiscal 2028 and includes the $4 billion Purification & Filtration divestiture. Wedbush said Solventum is seeing a convergence of catalysts that could unlock shareholder value.The investment firm added that Solventum's stock offers an attractive entry point at current levels for investors seeking exposure to a differentiated medical technology portfolio with identifiable near-term catalysts, activist accountability, and a clear path to pure-play re-rating.Wedbush initiated coverage with an outperform rating and a $94 price target.Price: 75.43, Change: +1.01, Percent Change: +1.36","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2635228033","isCrawlerRequest":true}